BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35659256)

  • 1. The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma.
    Wu SY; Xie ZY; Yan LY; Liu XF; Zhang Y; Wang DA; Dong J; Sun HT
    BMC Immunol; 2022 Jun; 23(1):28. PubMed ID: 35659256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
    Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
    Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma.
    Wu SY; Liao P; Yan LY; Zhao QY; Xie ZY; Dong J; Sun HT
    BMC Gastroenterol; 2021 Nov; 21(1):416. PubMed ID: 34724892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma.
    Guo B; Tan X; Cen H
    PLoS One; 2020; 15(11):e0242191. PubMed ID: 33180829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma.
    Chen Z; Lin X; Wan Z; Xiao M; Ding C; Wan P; Li Q; Zheng S
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
    Yu Z; Song Y; Cai M; Jiang B; Zhang Z; Wang L; Jiang Y; Zou L; Liu X; Yu N; Mao X; Peng C; Liu S
    Aging (Albany NY); 2021 Sep; 13(17):21294-21308. PubMed ID: 34470916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
    Song D; Wang Y; Zhu K; Tian L; Gao Q; Zhou J; Fan J; Wang X
    World J Surg Oncol; 2020 Jul; 18(1):176. PubMed ID: 32690026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy.
    Bae AN; Jung SJ; Lee JH; Lee H; Park SG
    Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208478
    [No Abstract]   [Full Text] [Related]  

  • 11. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, immune infiltration and clinical significance of SPAG5 in hepatocellular carcinoma: A gene expression-based study.
    Chen W; Chen X; Li S; Ren B
    J Gene Med; 2020 Apr; 22(4):e3155. PubMed ID: 31860771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
    Xu H; Xiong C; Chen Y; Zhang C; Bai D
    Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
    Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
    Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
    Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
    BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.
    Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
    Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
    Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinformatic Evidence Reveals that Cell Cycle Correlated Genes Drive the Communication between Tumor Cells and the Tumor Microenvironment and Impact the Outcomes of Hepatocellular Carcinoma.
    Chen D; Feng Z; Zhou M; Ren Z; Zhang F; Li Y
    Biomed Res Int; 2021; 2021():4092635. PubMed ID: 34746301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.